# US 2022/0033801 A1 · Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033801 A1
- Document ID: US20220033801A1
- Status: Published application
- Kind: A1
- Application number: 17/503,995
- Filed: 2021-10-18
- Published: 2022-02-03
- Earliest claimed: 2019-11-13
- Assignees: New York University
- Applicants: New York University
- Inventors: Richard NOVICK; Hope Forer ROSS; Geeta RAM
- Web page: https://patentgrep.com/patent/US20220033801A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N 2310/11: Antisense
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12Y 304/24075: Lysostaphin (3.4.24.75)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

Provided are modified Staphylococcus aureus pathogenicity islands of a variety of types and origins. The pathogenicity island are characterized as having a polynucleotide comprising a bacterial pathogenicity island nucleotide sequence (a “B-PINS”) that contains one or more modifications (“modified B-PINS”), that include i) a deletion or disruption of at least one virulence determinant of the B-PINS; and ii) an insertion of at least one cargo sequence. The polynucleotide are capable of being packaged within a bacterium into a phage-like particle that comprises a bacteriophage capsid, tail and tail fiber proteins in the form of an antibacterial drone (“ABD”). The ABD is capable of infecting bacteria such that at least one cargo sequence is introduced into bacteria infected by the ABD. Pharmaceutical and other compositions the ABDs are also included. Bacteria that make the ABDs are provided, as are isolated and/or purified ABDs. Methods of killing or otherwise modifying bacteria using the ABDs are also provided.

## Claims

### Claim 1

A polynucleotide comprising a bacterial pathogenicity island nucleotide sequence (B-PINS) comprising one or more modifications (a modified B-PINS),
wherein the one or more modifications comprise:
i) a deletion or disruption of at least one virulence determinant of the B-PINS; and
ii) an insertion of at least one cargo sequence into the B-PINS;
wherein the polynucleotide comprising the modified B-PINS is capable of being packaged within a bacterium into a phage-like particle that comprises or consists of bacteriophage capsid, tail and tail fiber proteins, and wherein the phage-like particle (an antibacterial drone “ABD”) is capable of infecting bacteria such that the at least one cargo sequence is introduced into bacteria infected by the ABD.

### Claim 2 (depends on 1)

The polynucleotide of claim 1, wherein the one or more modifications of i) comprises a deletion of all or substantially all of the virulence determinants in the B-PINS.

### Claim 3 (depends on 1)

The polynucleotide of claim 1, wherein the at least one cargo sequence comprises a polynucleotide sequence encoding an anti-bacterial agent that is functional against a target in at least some bacteria in a bacterial population.

### Claim 4 (depends on 3)

The polynucleotide of claim 3, wherein the anti-bacterial agent comprises one or a combination of:
a) a sequence encoding an RNA or DNA polynucleotide that comprises specificity for the target, wherein the target comprises an essential gene or an RNA encoded by an essential gene or a variable gene or an RNA encoded by a variable gene;
b) a sequence encoding a protein that has specificity for the target and can participate in and/or cause its cleavage and/or inactivation; or
c) a sequence encoding a toxin that is cytostatic against bacteria, or a non-toxin protein that inhibits growth of bacteria in the bacterial population or inhibits formation of and/or kills persister bacteria and/or dormant viable but non-culturable (VBNC) bacteria.

### Claim 5 (depends on 4)

The polynucleotide of claim 4, wherein a) comprises an anti-sense RNA.

### Claim 6 (depends on 4)

The polynucleotide of claim 4, wherein b) comprises a Clustered Regularly Interspaced Short Palindromic repeats (CRISPR) guide RNA targeted to a sequence in the bacteria in the bacterial population.

### Claim 7 (depends on 4)

The polynucleotide of claim 4, wherein the encoded protein of b) comprises a CRISPR-associated nuclease including but not limited to a Cas9 nuclease or a Cpf1 nuclease, or a dCas9.

### Claim 8 (depends on 4)

The polynucleotide of claim 4, wherein the toxin of c) comprises a toxin that kills bacteria that have been infected by the ABD.

### Claim 9 (depends on 8)

The polynucleotide of claim 8, wherein the toxin comprises lysostaphin.

### Claim 10 (depends on 4)

The polynucleotide of claim 4, wherein the toxin of c) comprises a toxin that is secreted by the bacteria and which is bactericidal against the bacteria and bacteria that are uninfected by the ADB.

### Claim 11 (depends on 4)

The polynucleotide of claim 4, wherein the target is comprised by a bacterial chromosome or a bacterial plasmid.

### Claim 12 (depends on 10)

The polynucleotide of claim 10, wherein the target confers antibiotic resistance.

### Claim 13 (depends on 1)

An ABD of claim 1, wherein the polynucleotide in the ABD further comprises a deletion of SaPI genes cpmA and/or B.

### Claim 14 (depends on 13)

A pharmaceutical composition comprising an ABD of claim 13.

### Claim 15 (depends on 13)

A method comprising administering a pharmaceutical or other composition comprising ABDs of claim 13 to an individual in need thereof, wherein subsequent to the administration bacteria in the individual are killed or exhibit reduced virulence.

### Claim 16 (depends on 15)

The method of claim 15, wherein prior to the administering, the method further comprises determining a characteristic of bacteria in the individual, and wherein the ABD is designed to comprise a cargo that has specificity for the characteristic.

### Claim 17 (depends on 16)

The method of claim 16, wherein the characteristic comprises a nucleotide sequence in the bacteria.

### Claim 18 (depends on 17)

The method of claim 17, wherein the nucleotide sequence comprises a sequence that can be recognized by a CRISPR system.

### Claim 19 (depends on 15)

The method of claim 15, wherein the ABD comprises a sequence encoding a toxin that is cytostatic against bacteria, wherein the toxin is optionally lysostaphin.

### Claim 20 (depends on 13)

A method for producing an ABD of claim 13 comprising growing bacterial cells comprising a polynucleotide comprising a bacterial pathogenicity island nucleotide sequence (B-PINS) comprising one or more modifications (a modified B-PINS),
wherein the one or more modifications comprise:
i) a deletion or disruption of at least one virulence determinant of the B-PINS; and
ii) an insertion of at least one cargo sequence into the B-PINS;
wherein the polynucleotide comprising the modified B-PINS is packaged within the bacteria to thereby produce the ABD.

### Claim 21 (depends on 20)

The method of claim 20, further comprising separating the ABD from the bacteria.

### Claim 22 (depends on 1)

A bacterial population comprising bacteria which comprise a polynucleotide of claim 1.

### Claim 23 (depends on 22)

The bacterial population of claim 22, wherein the population comprises a single distinct bacterial strain.

### Claim 24 (depends on 22)

Cell culture media comprising the bacterial population of claim 22.

### Claim 25 (depends on 13)

A bacterial population comprising ABDs of claim 13.

### Claim 26 (depends on 13)

A method comprising infecting a population of bacteria of with one or more ABDs of claim 13, thereby producing a gene drive effect whereby the cargo sequence carried by the one or more ABDs is disseminated to a plurality of bacteria in the population.

### Claim 27 (depends on 13)

A method comprising determining a target sequence in bacteria in a sample, generating or selecting an ABD of claim 13, and contacting the source of the sample with a plurality of the generated or selected ABD.

### Claim 28 (depends on 1)

A B-PINS of claim 1, wherein the B-PINS comprises a modified Staphylococcus aureus pathogenicity island (SaPI).

### Claim 29 (depends on 28)

The B-PINS of claim 28, wherein the SaPI is SaPI1, SaPI2, SaPIbov1, or SaPIbov2.

### Claim 30 (depends on 1)

A library of distinct ABDs of claim 1, wherein ABDs in the library comprise distinct nucleic acid sequences encoding distinct cargo.
